Says phase III trials showed 'no unexpected safety findings'. Armed with new phase III data, GlaxoSmithKline (GSK) has said it is on course to file for approval of its rheumatoid arthritis candidate sirukumab in 2016. Sirukumab is an interleukin-6 (IL-6) inhibitor, and one of a crop of new drugs that GSK has said could add at least Â£6bn to its revenues in 2020. The drug has been partnered with Johnson & Johnson's Janssen Biologics unit since 2011.
Agencies covered by the FAC-P/PM program may require additional training and experience beyond the basic FAC-P/PM requirements. Additional training is training in support of the agencyâs mission or the requirements of a program and project managerâs specific position.
Anyone who has a secondary degree and at least 1,500 hours of project team experience, or at least 23 hours of project management education, is eligible. These requirements are less strenuous than the Project Management Professional (PMP)Â® which requires both experience and education hours.